首页> 外文期刊>Contraception >Physical examination prior to initiating hormonal contraception: A systematic review
【24h】

Physical examination prior to initiating hormonal contraception: A systematic review

机译:开始荷尔蒙避孕之前的身体检查:系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Provision of contraception is often linked with physical examination, including clinical breast examination (CBE) and pelvic examination. This review was conducted to evaluate the evidence regarding outcomes among women with and without physical examination prior to initiating hormonal contraceptives. Study Design: The PubMed database was searched from database inception through March 2012 for all peer-reviewed articles in any language concerning CBE and pelvic examination prior to initiating hormonal contraceptives. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: The search did not identify any evidence regarding outcomes among women screened versus not screened with CBE prior to initiation of hormonal contraceptives. The search identified two case-control studies of fair quality which compared women who did or did not undergo pelvic examination prior to initiating oral contraceptives (OCs) or depot medroxyprogesterone acetate (DMPA). No differences in risk factors for cervical neoplasia, incidence of sexually transmitted infections, incidence of abnormal Pap smears or incidence of abnormal wet mount findings were observed. Conclusions: Although women with breast cancer should not use hormonal contraceptives, there is little utility in screening prior to initiation, due to the low incidence of breast cancer and uncertain value of CBE among women of reproductive age. Two fair quality studies demonstrated no differences between women who did or did not undergo pelvic examination prior to initiating OCs or DMPA with respect to risk factors or clinical outcomes. In addition, pelvic examination is not likely to detect any conditions for which hormonal contraceptives would be unsafe.
机译:背景:提供避孕措施通常与身体检查相关,包括临床乳房检查(CBE)和骨盆检查。进行此评价的目的是评估在开始使用激素避孕药之前是否进行身体检查的女性结局的证据。研究设计:从开始到2012年3月的PubMed数据库中,搜索在开始荷尔蒙避孕药具之前所有经同行评审的,涉及CBE和骨盆检查的任何语言的文章。使用美国预防服务工作队评分系统对每个研究的质量进行评估。结果:该搜索未发现任何有关在开始激素避孕之前接受过筛查和未接受CBE筛查的妇女结局的证据。该调查确定了两项质量相当的病例对照研究,比较了在开始口服避孕药(OCs)或醋酸甲羟孕酮(DMPA)之前接受或未接受骨盆检查的女性。未观察到子宫颈瘤形成,性传播感染的发生率,巴氏涂片异常的发生率或湿式坐骑发现的异常发生率的危险因素之间的差异。结论:尽管乳腺癌女性不应使用激素避孕药,但由于乳腺癌的发病率低且育龄妇女的CBE价值不确定,因此在开始使用前进行筛查的作用很小。两项高质量的研究表明,在开始使用OC或DMPA之前未接受盆腔检查的女性之间,在危险因素或临床结局方面没有差异。此外,骨盆检查不可能发现荷尔蒙避孕药不安全的任何情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号